Daneng Li, MD
Medical Oncology · Duarte, CANPI 1285877209
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2019 at $162,723 and has fallen 77.2% since, to $37,172 in 2025. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $998.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$108K
- Exelixis Inc.$76K
- Eisai Inc.$46K
- Lexicon Pharmaceuticals, Inc.$38K
- Advanced Accelerator Applications$31K
- Coherus Oncology, Inc.$26K
- plus $143K from 26 others
Across 551 payments — averaging $21,756 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3.8M
- AstraZeneca$3.1M
- Merck$2.5M
- Coherus Oncology, Inc.$1.2M
- AbbVie$573K
- Taiho Oncology, Inc.$296K
- plus $537K from 11 others
What the payments were for
- Consulting fees$167,82236%
- Speaking & faculty fees$249,48753%
- Travel & lodging$37,0888%
- Food & beverage$11,8083%
- Education$250%
- Charitable contribution$1,0000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 106 | $108,110 |
| Exelixis Inc. | 78 | $75,788 |
| Eisai Inc. | 51 | $46,101 |
| Lexicon Pharmaceuticals, Inc. | 39 | $37,817 |
| Advanced Accelerator Applications | 46 | $30,930 |
| Coherus Oncology, Inc. | 18 | $25,800 |
| AstraZeneca | 14 | $21,565 |
| Tersera Therapeutics LLC | 21 | $20,243 |
| Genentech, Inc. | 15 | $20,201 |
| Merck | 18 | $18,299 |
| Genentech USA, Inc. | 6 | $11,355 |
| AbbVie | 8 | $9,532 |
| Astrazeneca UK Limited | 3 | $9,179 |
| Servier Pharmaceuticals LLC | 6 | $5,411 |
| Sun Pharmaceutical Industries Inc. | 4 | $5,040 |
| Jazz Pharmaceuticals Inc. | 2 | $4,340 |
| F. Hoffmann-la Roche AG | 3 | $3,797 |
| Partner Therapeutics, Inc. | 8 | $3,711 |
| Boehringer Ingelheim International GmbH | 1 | $2,220 |
| Ipsen Innovation | 2 | $1,986 |
| Trisalus Life Sciences, Inc. | 2 | $1,562 |
| Novartis | 5 | $1,491 |
| Taiho Oncology, Inc. | 1 | $1,050 |
| Ipsen Pharma SAS | 1 | $910 |
| Sumitomo Pharma America, Inc. | 1 | $531 |
| Array Biopharma Inc | 1 | $97 |
| Bayer | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Bristol Myers Squibb | 1 | $22 |
| Johnson & Johnson | 1 | $16 |
| Pfizer | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$467,230 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 12 | $280,410 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $80,846 |
| Prochlorperazine Maleate | 11 | $148 |
| Ondansetron Hcl | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $46,101 | $280,41012 claims |
| NovartisSandostatin Lar Depot | $1,491 | $80,84612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 379 medical oncology providers in California.
Other medical oncology in Duarte
- Howard WestDuarte$426K
- Christine LovlyDuarte$362K
- Marwan FakihDuarte$203K
- Erminia MassarelliDuarte$176K
- Ravi SalgiaDuarte$142K
- Tanya DorffDuarte$136K
- Karen ReckampDuarte$132K
- Cy SteinDuarte$122K
- Joseph ChaoDuarte$110K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.